Friday, February 10, 2012
"Concise industry news from the US pharmaceutical industry..."
Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Blog
Spencer Green
Chairman, GDS International
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?25 May 2011
White Papers
Focus Area: Lead Features
Lead Features
Checkmate
Generic drugs, having long been minor players in the pharmaceutical marketplace, appear to be gaining a strategic advantage. Is this end game for branded products?
No Comments
A Limited Shelf Life?
Will President Obama’s health-care reforms scuttle plans by pharmaceutical companies to combat patent expiries by switching branded products to OTC? Schering-Plough’s Brent Saunders brings NGP’s Natalie Brandweiner up to speed.
No Comments
In with the New
When Chris Viehbacher arrived to take up the reins as CEO of sanofi-aventis, he found a company with an image problem that had forgotten how to communicate. Now he plans to change all that, as Marie Shields finds out.
No Comments
Source: www.ngpharma.com© 2012 GDS Publishing Ltd. All rights reserved.